



## **CORE BRIEF TO MANAGEMENT GROUP MEMBERS**

### **MEETING HELD ON 26 SEPTEMBER 2019**

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

#### **1. Welcome and Introductions**

The Chair welcomed members to the meeting.

#### **2. Minutes from Previous Meeting and Action Log**

The Minutes from the meetings held on 18 July and 22 August 2019 were noted.

Members noted the action log and received updates on:

- MG157 – MG19/061 Hereditary Anaemias – The work is more complicated than originally envisaged the action is therefore deferred to November 2019.
- MG158 – MG19/064 Policy Group – Post Implementation Review of Policies - The September Policy Group meeting was been postponed the action is therefore deferred to November 2019.
- MG164 – MG19/076 Tier 4 Specialist Perinatal Mental Health in Wales – Clinical Model - The revised paper was only been received from SBUHB on 24 September, so the action is deferred to October 2019.
- MG168 – MG19/082 CVUHB Cardiac Surgery Waiting List - The WHSS Team had become concerned about the increasing number of patients waiting more than 36 weeks; the improvement expected in September 2019 had not materialised. The WHSS Team will be writing the COO at CVUHB, stressing the importance of agreeing a performance management plan.

#### **3. Report from the Managing Director**

Members received the Managing Director's report, which included:

- **IVF Shrewsbury** No patients are waiting more than 52 weeks and the previously discussed error in calculating waiting periods has been rectified. De-escalation is expected to take place after completion of the August data analysis.
- **Paediatric Imaging** Due to the complicated nature of the work involved, consideration of the business case is postponed from this financial year to the development of the WHSSC 2020-23 ICP.

- **Vulnerable Persons Resettlement Scheme** The Home Office has confirmed that the number of refugees taken in by Welsh local authorities is expected to remain at around four cases per month and the WHSS Team has resumed discussions with the Home Office, Welsh Strategic Migration Partnership and Welsh Government about a pilot project, proposing that the WHSS Team advises on cases with medical conditions to confirm if they can be treated in Wales to inform the resettlement process.
- **Critically Ill Implementation Group – Paediatric Critical Care Provision, Stabilisation and Retrieval** Welsh Government intends to undertake work relating to paediatric critical care provisions and the stabilisation and retrieval of paediatric patients including services commissioned by WHSSC.
- **WHSSC Office Move** IT connectivity was achieved on 18 September 2019 following initial difficulties after the move at the end of August.

Members noted the contents of the report.

#### 4. Fetal Medicine

Members welcomed colleagues from CVUHB and received a presentation covering:

- Fetal Medicine Service
- Historical Perspective
- Existing Service and Infrastructure
- Service Shortfall
- Proposed Plans to Address Service Shortfall
- Benefits of Proposed Plan
- Patient Story
- Potential for Further Development

#### 5. Sentinel Node Biopsy

Members welcomed colleagues from SBUHB and received a presentation on Sentinel Node Biopsy with slides covering:

- Recap of service
- Why we do it
- Recent changes
- Patient pathway
- Workload
- Tracer safety issues
- Sentinel Mode Biopsy in Melanoma

#### 6. Interim Changes to the Delivery of the Cochlear Implant and BAHA Service for South Wales

Members received a paper the purpose of which was to provide an update on the interim changes to the delivery of Cochlear Implant and BAHA service for south Wales. The Cochlear service at Bridgend had been placed at Escalation Level 4 and suspended, pending further information and a meeting with the CTMUHB Executive Team to seek assurance around the areas of concern. It was reported that CTMUHB had worked

to source two audiologist in the past week and that a second ENT surgeon was being sought, all with a view to addressing the issues at Bridgend.

Members:

- Supported the interim changes that have been put in place to manage patients with immediate clinical need;
- Noted that until the management of patients requiring surgery was resolved, there was a risk that the south Wales Cochlear Implant programme would not meet the RTT waiting time target by 31 March 2020 and implement the NICE TA566;
- Noted that a letter had been sent to the Chief Operating Office at CTMUHB asking for plans to ensure that RTT could be achieved;
- Noted the options available for addressing the immediate commissioning concerns with the south Wales Cochlear Implant Programme; and
- Considered the long term solution that had been proposed by CVUHB.

## **7. Proposed Timelines for the Development and Submission of the 2020-23 WHSSC Integrated Commissioning Plan**

A first draft of the 2020-23 WHSSC Integrated Commissioning Plan will be presented to members for consideration at the October meeting and the final version presented to the Joint Committee on 12 November 2019 for approval.

## **8. Funding Release for Neurosurgery Referral to Treatment**

Members received a paper the purpose of which was to seek approval to release the funding allocated within the 2019-22 Integrated Commissioning Plan for the Neurosurgery Referral to Treatment scheme.

Members approved the release of the funding allocated within the 2019-22 Integrated Commissioning Plan for the Neurosurgery Referral to Treatment scheme.

## **9. Radiofrequency Ablation for Barrett's Oesophagus (RFA): CVUHB Business Case**

Members received a paper the purpose of which was to confirm that the RFA business case provided assurance that a safe service that met the quality standards of the service specification can be provided for patients; outlined the value for money of the proposal described in the business case for a RFA service in Cardiff; outlined the implementation plan for CVUHB to deliver a RFA service; and provided an assessment to inform the commissioning arrangements for provision of RFA for the population of south Wales.

Members:

- Noted that the Joint Committee had confirmed that WHSSC would commission the RFA service;
- Noted that Joint Committee had supported implementation of the RFA service as an in-year development;

- Noted that the business case outlined a service model that had sufficient capacity to treat expected demand for the south Wales population under current indications;
- Noted that the proposed service would provide better value for money than the current service provider in NHS England;
- Noted while the business case demonstrated compliance with key aspects of the RFA service specification, CVUHB had been asked to complete an explicit assessment against each aspect of the service specification to ensure that all the requirements of the specification were met;
- Approved the business case from CVUHB to deliver RFA for the mid and south Wales population subject to submission of a completed self-assessment against the service specification; and
- Noted that health boards would need to give notice to the current provider, Gloucester.

#### **10. Chimeric Antigen Receptor T Cell (CAR-T) Therapy: CVUHB Business Case**

Members received a report the purpose of which was to notify Management Group that the additional information required from CVUHB for approval of the CAR-T business case had been submitted to WHSSC and to confirm that WHSSC Corporate Directors Group Board had approved the business case and released funding for the CAR-T service development at CVUHB.

Members noted the content of the report.

#### **11. South Wales Sarcoma Service: Update on Action to Address Risks to Sustainability and Quality**

Members received the paper the purpose of which was to provide a position report on the status of the risks in the south Wales Soft Tissue Sarcoma service and the actions being taken to address them. Members noted a business case for a second sarcoma specialist was being considered internally by SBUHB.

Members noted the status of the risks in the south Wales Soft Tissue Sarcoma service and the actions being taken to address them.

#### **12. Funding Release for Neuro-Oncology**

Members received a paper that sought approval for the release of funding allocated within the 2019-22 Integrated Commissioning Plan for the Neuro-oncology scheme.

Members approved the release of funding allocated within the 2019-22 Integrated Commissioning Plan for the Neuro-oncology scheme.

#### **13. Major Trauma Centre: Tranche 2 Recruitment**

Members received a paper the purpose of which was to provide an update on the discussion regarding tranche 2 early recruitment for the Major Trauma Network at Joint Committee on 16 September 2019 and further

action delegated to Management Group. The paper also provided a synopsis of further discussion with CVUHB and agreement to make further changes to the business case, subject to approval by health boards and recommended support for the remaining tranche 2 posts for early recruitment.

Members:

- Noted the information presented in the report;
- Noted the outcome from Joint Committee and the additional scrutiny of the MTC with the agreed position with CVUHB; and
- Approved the early recruitment to the remaining tranche 2 posts, with the caveat that appointments are not made until end of October 2019 at the earliest and when health boards had considered the programme business case.

#### **14. WHSSC Policy Group Update**

Members received a paper on the work of the WHSSC Policy Group and noted the information presented within the report. 36 new clinical policies were in development.

#### **15. Integrated Performance Report**

Members received a report on the performance of services commissioned by WHSSC for June 2019 and noted the services in escalation and actions being undertaken to address areas of non-compliance.

#### **16. Finance Report 2019-20 Month 5**

Members received a report that set out the financial position for WHSSC for the fifth month of 2019-20, being an under spend of £455k and forecast underspend of £1,069k for the full year.

#### **17. Any Other Business**

- ***Advanced Therapy Medicinal Products ('ATMPs')***

It was reported that the long term financial forecast for ATMPs had been updated for Welsh Government.

- ***Commissioning & Value Based Procurement Workshop***

The WHSSC Planning Team will be presenting a masterclass at the workshop on 29 November 2019.

- ***Clinical Impact Assessment Group (CIAG)***

Papers for the CIAG meeting taking place on 3 October 2019 would be circulated later in the day.